袢利尿剂与老年患者后续使用泌尿症状药物的处方级联评估
该研究基于退伍军人事务部数据,采用处方序列对称分析,纳入2010-2019年起始袢利尿剂治疗的≥66岁退伍军人。总体未发现袢利尿剂至泌尿症状药物的处方级联信号(aSR 0.74),但在无基线泌尿症状的男性心衰患者(aSR 1.52)和多病共存患者(aSR 1.24)中观察到级联信号。
要点
- 总体老年男性中未发现袢利尿剂至泌尿症状药物的处方级联信号。
- 男性心衰患者(无基线泌尿症状)中观察到级联信号,aSR 1.52。
- 男性多病共存患者(Charlson第四四分位)中观察到级联信号,aSR 1.24。
核心结论
- 在主要为男性的老年退伍军人中,总体上未发现袢利尿剂至泌尿症状药物的处方级联证据。
- 临床医生可能对接受袢利尿剂的患者处方泌尿症状药物不足,或因将泌尿症状强烈归因于袢利尿剂使用。
研究设计与样本
- 处方序列对称分析,使用退伍军人事务部数据,纳入2010-2019年起始袢利尿剂治疗的≥66岁退伍军人。
- 计算调整序列比(aSR)以评估级联信号,并校正时间趋势,按关键变量分层。
主要发现
- 总体aSR为0.74(95% CI,0.73-0.76),意味着袢利尿剂起始后6个月内起始泌尿症状药物的可能性比前6个月低26%。
- 男性中aSR为0.74(95% CI,0.72-0.76),女性中aSR为1.00(95% CI,0.80-1.26)。
- 在无基线泌尿症状的男性中,心衰患者aSR为1.52(95% CI,1.41-1.63),多病共存患者(Charlson第四四分位)aSR为1.24(95% CI,1.10-1.39)。
关键数值与推荐
- 泌尿症状药物包括抗胆碱能药、β-3肾上腺素能激动剂、外周α-1阻滞剂和5-α还原酶抑制剂。
- 主要结局指标为调整序列比(aSR),评估袢利尿剂起始后6个月相对于前6个月泌尿症状药物起始的比值。
临床怎么用
- 临床医生应警惕心衰和多病共存老年男性患者中袢利尿剂可能引发的泌尿症状药物处方级联。
- 对于接受袢利尿剂的患者,应评估泌尿症状是否由药物引起,避免不必要的泌尿症状药物处方。
局限性
- 研究人群99%为男性,结果外推至女性受限。
- 处方序列对称分析可能受时间趋势和未测量混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Loop diuretic (LD) use may lead to a prescribing cascade whereby urinary symptoms are ascribed to genitourinary syndromes and treated with urinary symptom medications (USMs). We investigated if LDs lead to increased USM use among older adults and whether this potential prescribing cascade varies across key characteristics. METHODS: This was a prescription sequence symmetry analysis of Veterans Administration data, involving veterans ≥66 years who initiated treatment with LD (2010-2019). USMs were antimuscarinics, beta-3 adrenergic agonists, peripheral alpha-1 blockers, and 5-alpha reductase inhibitors. We calculated the adjusted sequence ratio (aSR), assessing the cascade signal while adjusting for secular trends, and stratified by key variables. RESULTS: There were 17 735 veterans who initiated USM within 6 months after LD and 25 190 who initiated USM within 6 months before LD; 99% were male. Unexpectedly, the aSR was 0.74 (95% CI, 0.73-0.76), meaning patients were 26% less likely to initiate USM within 6 months after initiating LD versus 6 months before. This inverse relationship held in men (aSR, 0.74, 95% CI, 0.72-0.76) but was null in women (aSR, 1.00, 95% CI, 0.80-1.26). In men without baseline urinary symptoms, we observed the LD-USM cascade in patients with heart failure (aSR 1.52, 95% CI, 1.41-1.63) and multimorbidity (eg, Charlson fourth quartile, aSR 1.24, 95% CI, 1.10-1.39). CONCLUSIONS: We did not find evidence for an LD-USM cascade among predominantly male older adults overall. Clinicians may underprescribe USMs in patients receiving LDs, perhaps due to strong attribution of urinary symptoms to LD use.
引用
- Growdon ME, Jing B, Deardorff WJ, et al. Loop diuretics and subsequent use of urinary symptom medications in older adults: evaluation of a possible prescribing cascade. J Gerontol A Biol Sci Med Sci. 2025. PMID: 40668217. doi:10.1093/gerona/glaf150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。